AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
Source
Endpoints
AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda
Source
Fierce Pharma
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?
Source
Endpoints
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Source
Market Realist